The present invention is directed to providing a method of manufacturing a fluorine-containing compound according to which a fluorine-containing compound is manufactured under a relatively moderate reaction condition by use of a readily available compound. A method of manufacturing a fluorine-containing compound includes reacting a compound having a partial structure expressed by a formula (a) below with a Grignard reagent in the presence of a transition metal compound,

—CF.sub.2—CH.sub.2—L  (a)

wherein L is a sulfonate group.

The present invention is directed to providing a method of manufacturing a fluorine-containing compound according to which a fluorine-containing compound is manufactured under a relatively moderate reaction condition by use of a readily available compound. A method of manufacturing a fluorine-containing compound includes reacting a compound having a partial structure expressed by a formula (a) below with a Grignard reagent in the presence of a transition metal compound,

—CF.sub.2—CH.sub.2—L  (a)

wherein L is a sulfonate group.

A catalyst may include a support and from 5 to 20 wt.-% of a promoter, based on the total weight of the catalyst, wherein the support may include titanium dioxide, zirconium dioxide, and/or a mixture thereof, and the promoter may be an alkali metal oxide. Processes for preparing such catalysts may include impregnating a support of titanium dioxide and/or zirconium dioxide with an aqueous solution including a preferably soluble alkali compound and calcining. Alkyl mercaptans may be prepared in the presence of such catalysts or catalysts obtained by such processes.

A catalyst may include a support and from 5 to 20 wt.-% of a promoter, based on the total weight of the catalyst, wherein the support may include titanium dioxide, zirconium dioxide, and/or a mixture thereof, and the promoter may be an alkali metal oxide. Processes for preparing such catalysts may include impregnating a support of titanium dioxide and/or zirconium dioxide with an aqueous solution including a preferably soluble alkali compound and calcining. Alkyl mercaptans may be prepared in the presence of such catalysts or catalysts obtained by such processes.

The present invention relates to a process for manufacturing of anhydrous methanesulfonic acid (MSA) and to methanesulfonic acid manufactured by said process and its uses.

The present invention relates to a process for manufacturing of anhydrous methanesulfonic acid (MSA) and to methanesulfonic acid manufactured by said process and its uses.

The disclosure is in part directed to crystalline forms of N-(4-(4-amino-5-(3-fluoro-4-(4-methylpyrimidin-2-yl)oxy)phenyl)-7-methyl-7H-pyrrolo[2,3-d]pyrimidin-6-yl)phenyl)methacrylamide, its salts, its cocrystals, and variants thereof.

The invention relates generally crystalline mesylate salts, crystalline chloride salts and crystalline sulfate salts of the compound (S)-2-(3′-(hydroxymethyl)-1-methyl-5-((5-(2-methyl-4-(oxetan-3-yl)piperazin-1-yl)pyridin-2-yl)amino)-6-oxo-1,6-dihydro-[3,4′-bipyridin]-2′-yl)-7,7-dimethyl-2,3,4,6,7,8-hexahydro-1H-cyclopenta[4,5]pyrrolo[1,2-a]pyrazin-1-one that is an inhibitor of Bruton's tyrosine kinase. In some aspects, the crystalline salts are single polymorphs.

The invention relates generally crystalline mesylate salts, crystalline chloride salts and crystalline sulfate salts of the compound (S)-2-(3′-(hydroxymethyl)-1-methyl-5-((5-(2-methyl-4-(oxetan-3-yl)piperazin-1-yl)pyridin-2-yl)amino)-6-oxo-1,6-dihydro-[3,4′-bipyridin]-2′-yl)-7,7-dimethyl-2,3,4,6,7,8-hexahydro-1H-cyclopenta[4,5]pyrrolo[1,2-a]pyrazin-1-one that is an inhibitor of Bruton's tyrosine kinase. In some aspects, the crystalline salts are single polymorphs.

Provided are a salt form and a crystal form of adenosine A.sub.2A receptor antagonist, and preparation method therefor. Also provided is an application of the salt form or crystal form in the preparation of a medicine for A.sub.2A receptor-related diseases, the maleate salt in the salt form has a structure of formula (I).

##STR00001##